Genomic (e.g., PNPLA3 polymorphism) (68) and phenotypic (e.g., sarcopenic vs. central obesity phenotypes) (69) stratification could optimize treatment selection, improving response rates and minimizing side effects. This evidence concerns the gene PNPLA3 and Abdominal obesity.